Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Haber

Showing results (51-60 of 186) with videos related to

Pageof 19
Sort By:
Journal of the National Cancer Institute|September 18, 2003
Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastomaCatherine A Burkhart, Andy J Cheng, Janice Madafiglio, et al.
Blood|October 9, 2014
GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesisPhilipp A Dietrich, Chen Yang, Halina H L Leung, et al.
Cancer Letters|January 17, 2009
The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylationAnna Raif, Glenn M Marshall, Jessica L Bell, et al.
JNCI Cancer Spectrum|July 31, 2019
Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian CancerMoonSun Jung, Amanda J Russell, Catherine Kennedy, et al.
Oncotarget|July 5, 2016
Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growthOrazio Vittorio, Miriam Brandl, Giuseppe Cirillo, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2004
Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplificationLoen M Hansford, Wayne D Thomas, Joanna M Keating, et al.
Cancer Cell|October 13, 2020
Advances and Challenges in Pediatric and Childhood CancersCynthia Hawkins, Stefan Pfister, David T W Jones, et al.
Biochemical Pharmacology|July 15, 2019
MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cellsChristine C Gana, Kimberley M Hanssen, Denise M T Yu, et al.
Cancer Immunology, Immunotherapy : CII|April 4, 2008
Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancerBenjamin B Williams, Meg Wall, Rebecca Yu Miao, et al.
Molecular Cancer Therapeutics|April 14, 2005
Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitroMurray D Norris, Janice Smith, Kara Tanabe, et al.
Pageof 19

Showing results (51-60 of 186) with videos related to

Sort By:
Pageof 19
Journal of the National Cancer Institute|September 18, 2003
Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastomaCatherine A Burkhart, Andy J Cheng, Janice Madafiglio, et al.
Blood|October 9, 2014
GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesisPhilipp A Dietrich, Chen Yang, Halina H L Leung, et al.
Cancer Letters|January 17, 2009
The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylationAnna Raif, Glenn M Marshall, Jessica L Bell, et al.
JNCI Cancer Spectrum|July 31, 2019
Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian CancerMoonSun Jung, Amanda J Russell, Catherine Kennedy, et al.
Oncotarget|July 5, 2016
Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growthOrazio Vittorio, Miriam Brandl, Giuseppe Cirillo, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2004
Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplificationLoen M Hansford, Wayne D Thomas, Joanna M Keating, et al.
Cancer Cell|October 13, 2020
Advances and Challenges in Pediatric and Childhood CancersCynthia Hawkins, Stefan Pfister, David T W Jones, et al.
Biochemical Pharmacology|July 15, 2019
MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cellsChristine C Gana, Kimberley M Hanssen, Denise M T Yu, et al.
Cancer Immunology, Immunotherapy : CII|April 4, 2008
Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancerBenjamin B Williams, Meg Wall, Rebecca Yu Miao, et al.
Molecular Cancer Therapeutics|April 14, 2005
Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitroMurray D Norris, Janice Smith, Kara Tanabe, et al.
Pageof 19